More than half a century after the discovery of the first antidepressant drug, the drug
treatment of depressive disorders is still a major problem, due to the high interindividual …

This work aimed to describe and characterize the GnG-PK/PD-AD study and the population
of subjects diagnosed with depression and treated with fluoxetine, paroxetine, and …

This work presents the GnG-PK/PD-AD study—a pharmacokinetics/pharmacodynamics
(PK/PD) analysis of the impact of genetic and nongenetic factors on the treatment with the …

Drug therapy is the primary modality for depression; however, its outcome is often
unpredictable, ranging from beneficial effects to serious adverse effects. Genetic variations …

This review examines the role of drug metabolism and drug target polymorphism in
determining the clinical response to antidepressants. Even though antidepressants are the …

Introduction: Pharmacogenomics, which is derived from genome-wide association studies
(GWAS), and pharmacogenetics, which involves candidate gene association studies …

Venlafaxine (VEN) is one of the safest and most effective drugs used in the treatment of
selective serotonin reuptake inhibitors-resistant depression, and thereby it is nowadays one …

Introduction: The cytochrome P450 (CYP) enzymes are the major enzymes responsible for
Phase I reactions in the metabolism of several substances, including antidepressant …

Numerous studies in the field of psychopharmacological treatment have investigated the
possible contribution of genetic variability between individuals to differences in drug efficacy …

Fluoxetine is one of the most prescribed antidepressants, yet it still faces challenges due to
high intersubject variability in patient response. Mainly metabolized by the highly …